Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL286918 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL18696151 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL8318136 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL7325420 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL14486114 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL8318140 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL14486115 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL28219869 | 0.96 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL28837862 | 0.92 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL9395845 | 0.92 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4534881-A | Inhibition of inorganic or biological CaCO3 deposition by poly amino acid derivatives | UNIVERSITY OF SOUTH ALABAMA (US) | 1985-08-13 | — | — | US | claimed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| CN-115844896-A | Methods of treating arenaviridae and coronaviridae virus infections | 吉利德科学公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3737420-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10369091-B2 | Core shell silica particles and uses thereof as an anti-bacterial agent | COLGATE-PALMOLIVE COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| WO-2019136487-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20160338920-A1 | CORE SHELL SILICA PARTICLES AND USES THEREOF AS AN ANTI-BACTERIAL AGENT | COLGATE PALMOLIVE CO (US) | 2016-11-24 | — | — | US | disclosed |
| EP-2427775-A1 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS | BCN Peptides, S.A. (ES) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128098-A1 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS | BCN PEPTIDES, S.A. (ES) | 2010-11-11 | — | — | WO | disclosed |
| CN-1895066-A | Anti-body leben tablet (powder) | GOU CHUNHU (CN) | 2007-01-17 | — | — | CN | disclosed |
| US-6107471-A | AMINO ACID AND NUCLEOTIDE SEQUENCE OF ENZYME WHICH SPLITS PEPTIDES AT C-TERMINAL SIDE OF ASPARAGINE; FOR PRODUCTION AND GENETIC ENGINEERING OF ENZYME | DIRECTOR OF NATIONAL FOOD RESEARCH INSTITUTE, MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES (JP) | 2000-08-22 | — | — | US | disclosed |
| US-5747050-A | COSMETICS WITH SODIUM CHLORIDE AND PEAT | TORF ESTABLISHMENT (LI) | 1998-05-05 | — | — | US | disclosed |
| US-5428171-A | Leukotrienes antagonist; antiasthmatic, antiallergic, anti-inflammatory and cytoprotective agent | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| WO-1994013629-A1 | MANNITOL DERIVATIVES AND THEIR USE AS INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-06-23 | — | — | WO | disclosed |
| US-5112808-A | Promotes release of growth hormone | AMERICAN CYANAMID COMPANY (US) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338920-A1 | CORE SHELL SILICA PARTICLES AND USES THEREOF AS AN ANTI-BACTERIAL AGENT | SRI, CAPG, SAE1 | SLC7A5 1816/4885SLC1A3 3772/4885SLC1A2 4124/4885 |
| US-10369091-B2 | Core shell silica particles and uses thereof as an anti-bacterial agent | SRI, CAPG, SAE1 | SLC7A5 1816/4885SLC1A3 3772/4885SLC1A2 4124/4885 |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | SLC7A5 1891/4885SLC1A3 3392/4885SLC1A2 3978/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | SLC7A5 1891/4885SLC1A3 3392/4885SLC1A2 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.